2018-12-11 12:00 - Maintenance complete.

Opioid receptor stimulation acts as mediator of protection in ischaemic preconditioning

Genade S. ; Moolman J.A. ; Lochner A. (2001)


Involvement of the opioid receptors in preconditioning-induced protection has recently been described. The aims of this study were to establish whether: (i) opioid receptor stimulation acts as a trigger (during the preconditioning protocol) or as a mediator (during sustained ischaemia) of cardioprotection using either morphine or [D-ala2, D-leu5] enkephalin (DADLE), a synthetic δ-opioid receptor agonist; (ii) the beneficial effects of DADLE are protein kinase C (PKC)-mediated; and (iii) inhibitory 'cross-talk' occurs between the β-adrenergic and phosphatidylinositol pathways activated by release of endogenous catecholamines and opioids respectively during sustained ischaemia. The isolated, perfused working rat heart, subjected to 25 minutes' global ischaemia and 30 minutes' reperfusion, was used as the experimental model. The results showed that δ-opioid receptor stimulation with DADLE (10-8 M), when administered for 3 × 5 minutes, had no effect, while when given 10 minutes before sustained ischaemia the drug significantly improved functional recovery during reperfusion. This indicates that opioid receptor stimulation acts as a mediator rather than a trigger in the protection elicited. Morphine (3 × 10-7) when administered in the same manner was without effect. Opioid receptor stimulation caused a marked reduction in the β-adrenergic response to isoproterenol, indicating inhibitory cross-talk between the phosphatidyl-inositol and β-adrenergic signal transduction pathways. However, reduction of the β-adrenergic response to ischaemia does not appear to be the mechanism of opioid-induced protection, as indicated by 3′,5′-cyclic adenosine monophosphate (cAMP) levels at the end of 25 minutes' global ischaemia. Opioid receptor-mediated protection against ischaemic damage is PKC-dependent, since DADLE-induced protection could be abolished by the inhibitor chelerythrine.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/10013
This item appears in the following collections: